Clinical utility of eco-color-power Doppler ultrasonography and contrast enhanced magnetic resonance imaging for interpretation and quantification of joint synovitis: a review

Marina Carotti, Vittoria Galeazzi, Francesca Catucci, Marcello Zappia, Francesco Arrigoni, Antonio Barile, Andrea Giovagnoni

1 Azienda Ospedaliera Universitaria, Ospedali Riuniti di Ancona, Dipartimento di Scienze Radiologiche S. O. D. Radiologia Pediatrica e Specialistica, Ancona; 2 Scuola di Specializzazione in Radiodagnostica, Università Politecnica delle Marche, Ancona; 3 Dipartimento di Medicina e di Scienze della Salute “Vincenzo Tiberio”, Università del Molise, Campobasso; 4 Dipartimento di Radiodiagnostics, Ospedale S. Salvatore, Dipartimento di Scienze cliniche applicate e biotecnologiche Università degli Studi dell’Aquila (AQ); 5 Azienda Ospedaliera Universitaria, Ospedali Riuniti di Ancona, Dipartimento di Scienze Radiologiche S. O. D. Radiologia Pediatrica e Specialistica, Università Politecnica delle Marche, Ancona

Summary. With the introduction of new biologics such as anti-TNF-alpha antibodies and other therapies in the treatment of inflammatory arthritis, capable of halting joint destruction and functional disability, there are new pressures on diagnostic and prognostic imaging. Early demonstration of pre-erosive inflammatory features and monitoring of the long-term effects of treatment are becoming increasingly important. Early detection of synovitis offers advantages in terms of allowing early instigation of therapy and may allow the identification of those patients displaying more aggressive disease who might benefit from early intervention with expensive DMARD therapy. Advanced imaging techniques such as ultrasound (US) and magnetic resonance imaging (MRI) have focussed on the demonstration and quantification of synovitis and allow early diagnosis of inflammatory arthropathies such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Synovitis represents a potential surrogate measure of disease activity that can be monitored using either MRI or US; the techniques have, generally, focused on monitoring synovial volume or quality as assessed by its vascularity. However to achieve these goals, standardisation and validation of US and MRI are required to ensure accurate diagnosis, reproducibility and reliability. Each modality has different strengths and weaknesses and levels of validation. This article aims to increase the awareness of radiologists and rheumatologists about this field and to encourage them to participate and contribute to the ongoing development of these modalities. Without this collaboration, it is unlikely that these modalities will reach their full potential in the field of rheumatological imaging. This review is in two parts. The first part addresses the role of US and colour or power Doppler sonography (PDUS) in the detection and monitoring of synovitis in inflammatory arthropathies. The second part will look at advanced MR imaging and Dynamic contrast-enhanced MRI techniques and in particular how they are applied to the monitoring of the disease process. (www.actabiomedica.it)

Key words: rheumatoid arthritis, psoriatic arthritis, synovitis, magnetic resonance imaging, ultrasound, clinical trials

Introduction

Synovitis (inflammation of the synovium) is a characteristic feature of chronic inflammatory arthritis, and is considered an important factor in the chronicity of the disease and the best predictive marker of joint damage (1, 2). Proliferation of the synovial tissue resulting in the formation of the pannus is an early
event in the course of the rheumatic diseases and can be seen before destruction of cartilage and bone (3).

New blood vessel formation seems to be one of the many variables required in the pathogenesis of proliferative synovitis, of which rheumatoid arthritis (RA) is the prototype.

Under normal conditions, the synovium maintains a delicate balance between proangiogenic and antiangiogenic forces. In the inflammatory synovium, however, this balance is lost and there is an increase in proangiogenic factors, ultimately leading to endothelial cell proliferation and pannus growth. Accurate assessment of synovitis is essential in rheumatologic practice to make therapeutic decisions and to evaluate the response to treatment.

Ultrasoundography (US) offers a non-invasive, reproducible, non-radiating, and relatively inexpensive method for detecting joint effusion and bursal fluid collection and may depict hyperplastic synovium and underlying erosive disease. However, it does not provide direct information about haemodynamic alterations, which may occur in soft tissue inflammation. Color Doppler US/Power Doppler US (CDUS/PDUS) is important in distinguishing complex effusion and pannus and in the assessment of vascular abnormalities at the synovial tissue. Several studies demonstrated that US, CDUS/PDUS and magnetic resonance imaging (MRI) are more sensitive than clinical examination in detecting synovitis (4-7) and in particular for large joints such as the shoulder and knee (8-10). An important issue consists of the possibility of identifying subclinical synovitis, being subclinical inflammation not an uncommon feature in rheumatic disease.

Ultrasound contrast agents enhance visualization of the small synovial vessels, can be used to estimate haemodynamic alterations and may have a role in assessing synovial activity and in distinguishing between inflammatory and non-inflammatory pannus. Estimation of the area under US contrast enhancement curves may help to produce a method of measuring synovial activity and in evaluating the efficacy of the therapeutic regimens.

MRI allows excellent viewing of all components of the joint simultaneously. MRI depicts soft tissue changes and damage to cartilage and bone and it is the only imaging modality that depicts bone marrow oedema, an MRI feature that is strongly associated with disease progression (11). It is an excellent tool to assess synovial swelling and volume. Dynamic MRI allows direct visualisation of the inflamed synovium in patients with arthritis and it may be considered the gold standard assessment technique (12, 13).

This review describes imaging modalities available and their main applications in patients with inflammatory arthritis and discusses the evidence and advantages supporting their use.

**Imaging modalities**

**Ultrasoundography**

Ultrasound is an evolving technique and the rapid progress in ultrasound technology over the past ten years has dramatically increased its range of applications in rheumatology. US is used to detect, assess, and quantify both the inflammation of joints and structural damage caused by a variety of rheumatic diseases (14). Ultrasonic wave pulses hitting tissue interfaces produce echowaves that form US images. A large number of studies have clearly demonstrated that US examination of joints has a higher sensitivity for detecting synovitis than does physical examination (15-19).

US allows the visualization of the morphologic structures of the joints and surrounding tissue, such as tendons, and the differentiation of fluid and solid structures and between synovial inflammation and tenosynovitis, bursitis and other soft tissue lesions that can mimic clinical synovitis, but does not provide colour maps of tissue and direct information about haemodynamic alterations, which may occur in soft tissue inflammation. By US minimal changes of volume within a joint due to effusion or synovitis can be detected more sensitive than with clinical examination (20), especially in subclinical alterations.

To ensure that musculoskeletal ultrasonography findings are comparable, it is important to use a standardized examination procedure and to define typical pathologies (21, 22). According to EULAR (European League Against Rheumatism) and OMERACT (Outcome Measures in Rheumatology Clinical Trials) Ultrasound Task Force (23) effusion is defined as the
abnormal presence of hypoechoic or anechoic intra-articular material that is displaceable and compressible, but does not exhibit a Doppler signal, while synovial hypertrophy or proliferation is represented by the abnormal presence of hyperechoic intra-articular tissue that is nondisplaceable and poorly compressible, and might also exhibit a Doppler signal. An inflammatory status at joint level is characterized by the presence of synovial effusion and/or hypertrophy and by the increase of local vascularization. In the presence of synovial hypertrophy, the application of PD and CD techniques can help in differentiating between effusion and pannus and between active and inactive inflammation (24).

Synovitis, either proliferative or exudative, can be ultrasonographically graded. Its quantification via grayscale ultrasound usually uses a semiquantitative scale with three levels of intensity, indicating mild, moderate or marked synovial changes (Figure 1) (25, 26).

**Spectral Doppler**

Doppler ultrasonography is primarily used for the hemodynamic assessment of blood vessels. Doppler technique is based on the physical phenomenon, which consists of a change in the frequency of a sound wave resulting from motion of either the source or the receiver and reflect, giving us information about the movement of objects such as red blood cells in vessels. Spectral Doppler allows us to measure different blood flow parameters, some of which, such as the resistive index (RI), can be used to assess synovial inflammation.

In the cerebral and renal arteries, high diastolic flow is normal because low peripheral resistance is essential for continuous high perfusion. Conversely, normal blood flow in musculoskeletal tissues is characterized by high resistance, because the diastolic velocity has been considered to be zero, so the RI, which is the ratio between the systolic peak minus the end diastolic flow and the systolic peak, has a value of 1 in normal conditions; a decrease in the RI is registered in case of inflammation or neo-angiogenesis (27) (Figure 2).

The inflammatory process is characterized by an increased perfusion and permeability of vessels and neovascularization and consequently an increased of the diastolic velocity and decreased RI at the level of inflamed synovium. Therefore, cut-off levels of RI are necessary to differentiate pathological flow from synovitis – like changes that can be documented also in healthy subjects. In addition, cut-off levels of RI are necessary to differentiate pathological flow from nor-
mal perfusion that can be found in joints of healthy control subjects. Terslev et al. (28) have reported a cutoff level of RI in healthy subjects ranging from 0.83 to 0.90. In another study Terslev et al. (29) reported a mean RI of 0.80 at the wrist and metacarpophalangeal joints in healthy subjects, which was higher than the values in the range of 0.4–0.76 reported in the literature for patients with rheumatoid disease (28).

More recently, we found a significant difference between mean RI at the wrist and finger joints in patients with rheumatoid disease and healthy subjects (0.72 versus 0.86, respectively) (30). We, also, observed a significant difference in mean RI between patients with early onset and those with long-standing disease (0.71 versus 0.74). Inflammation leads to increased blood flow in synovial and peri articular tissue, at tendon insertions, and in tendon sheaths, which can be detected by CD ultrasonography. In addition, in clinical practice, spectral Doppler can be useful to distinguish real flow versus artefacts in some occasional doubtful cases.

In inflammatory arthritis, color or power Doppler signals within synovial hypertrophy is the main pathologic marker of inflammatory activity (31, 32).

**Color Doppler Ultrasound**

CD mode can detect pathological synovial blood flow, which reflects the joint inflammatory activity (33). CD ultrasound generates a real-time map of colored pixels in the gray scale setting, showing sites of blood flow in the area of interest defined by the Doppler box.

The color of the signal indicates the direction of blood flow, with red spots generated by blood flow directed toward the probe and blue ones away from it. The flow direction is arbitrarily assigned the colour red or blue, indicating flow toward or away from the transducer. No signal is displayed if the direction of blood flow is perpendicular to the ultrasound beam.

CD gives any information about the number of moving cells. The CDUS technique is affected by the direction of blood flow, whereas the images obtained by PDUS are not direction-coded. PDUS is, therefore, able to detect a very slow blood flow rate.

A number of studies have shown the ability of CD to detect synovial vascularization in patients with chronic inflammatory arthritis, to differentiate between normal and abnormal blood flow and between inactive and active pannus, and to assess changes in synovial blood flow induced by different treatments. However, CD findings can be found at the wrist and metacarpophalangeal joints in healthy subjects (28, 30). Terslev et al. (28) scanned 324 joints in 27 healthy subjects, and found color Doppler signals in 15 of 27 wrists, 17 of 27 first carpometacarpal joints, 10 of 135 metacarpophalangeal joints, and 1 of 135 proximal interphalangeal joints. Previously, we observed color Doppler signals in 45 of the 430 joints of healthy subjects and the positive Doppler findings were most common in the wrists, followed by metacarpophalangeal joints and proximal interphalangeal joints (30).

Several methods have been proposed for scoring intra-articular color Doppler signals (34). The two main methods are the semiquantitative scoring system, which assesses the amount of color Doppler signals using a four-point grading scale, and the quantitative scoring system, which counts color pixels in synovial tissue using dedicated post-processing software. The semiquantitative method allows for more rapid assessment, and relies on the skills and experience of the sonographer, whereas the quantitative method, with computer-assisted measurement of color pixels 12 on the basis of either an absolute number of pixels, or a percentage of an area covered with pixels, in a region of interest, has the potential to be more reproducible, but requires more time (35). In a recent study, Terslev et al. (36) compared these two methods when scoring at the wrists of 46 rheumatoid patients in the dorsal view and a high correlation and comparable inter-reader agreement was found between these scoring systems.

**Power Doppler Ultrasound**

Power Doppler encodes the amplitude of the Doppler signal resulting from the volume of blood present, regardless of direction and speed, thereby detecting flow also in case of perpendicularity of the flow to the US beam and enables sensitive assessment of low-velocity flow in small vessels of the synovial tissue, thus being more appropriate for the analysis of neo-angiogenesis (37, 38). Recent data suggested that
PD can provide more accurate data than grey scale for synovitis in RA (39). Even if, using last-generation ultrasound equipment, substantial difference between color and power Doppler with regard to detection of slow flow was not found (40), the majority of studies investigating the role of ultrasound in patients with chronic inflammatory arthritis have been performed using power Doppler.

A number of studies showed the validity and reliability of power Doppler in the assessment of vascularized synovium in joints and tendon sheaths in patients with chronic inflammatory arthritis and a strong correlation was found between the qualitative estimates of blood flow obtained by PDUS and synovial blood vessel density in a histological tissue section (41-43). PDUS has also been validated against other modalities including contrast-enhanced MRI scanning (44), considered as the gold standard assessment technique. Walther et al. (43) compared PD and synovial histopathology of the knee joint in 23 patients (10 affected by RA, 13 by OA), who were undergoing total knee arthroplasty. They evaluated both grey-scale and PD synovitis, quantifying them on a 4-point scale, according to the Newman score (45) and adding an automatic quantification of red pixels a sign of vascularization. Both the qualitative and the quantitative estimation of vascularization correlated with the histopathological findings, leading to the conclusion that PD is a valid tool for the detection and quantification of synovial vascularization (43). One year later, a similar work was done on the hip using the same protocol (24 patients, 15 with OA and 9 with RA); the results showed a good correlation between histological findings and PD in the detection of synovial vascularity (46).

When contrast-enhanced MRI (CE-MRI) has been used for assessing the validity of PD, a good correlation between the two techniques has been shown (47). Szudlarek et al. (44) showed a good correlation between power Doppler signals and contrast-agent enhancement in MRI for visualizing active synovitis and the sensitivity and specificity of CD/PD Doppler ultrasonography compared with MRI were 89% and 98%, respectively, for the assessment of inflammation in metacarpophalangeal joints in patients with RA.

Several studies have evaluated the validity of power Doppler in the assessment of synovitis in patients with inflammatory arthritis (48). Kaoru Takase-Minegishi et al. (49) in their systematic review and meta-analysis of studies evaluating the diagnostic test accuracy of US for synovitis detected by MRI as the reference standard for wrist, metacarpophalangeal joints, proximal interphalangeal joints and knee joints of patients with RA, found that US, especially power Doppler US, is a valid and reproducible technique for detecting synovitis in the wrist and finger joints of these patients.

In a number of studies, the presence of synovial Doppler signal has shown diagnostic value in relation to the development of chronic arthritis or RA in patients with early undifferentiated synovitis (50-52). Some PDUS signs can help to distinguish RA from other causes of arthritis. Gutierrez et al. (53) found that in early psoriatic arthritis hypoechoic swelling surrounding the extensor digitorum tendon and peri-tendinous PD signal seem to predominate compared with intra-articular PD signal in early RA (Figure 3). This study supports the hypothesis that the extra-articular tissue involvement seems to be characteristic of spondyloarthritis rather than RA (54). Addition-
ally, it was noted that the peritenon extensor tendon inflammation pattern was frequently observed in patients with short time of disease duration. According to this observation, it is believed that the inflammatory process in psoriatic arthritis (PsA) could begin at the soft tissue level surrounding the extensor digitorum tendon, successively involving the synovial membrane (55), whereas an isolate synovitis could be detected in the late stages of PsA disease. These preliminary results suggest a relevant potential role for PDUS in the differential diagnosis between RA and PsA.

PDUS has several potential roles in gout diagnosis. It has shown diagnostic value in detecting early changes in the soft tissues in cases of gout and can be used especially when the clinical, laboratory and radiographic studies are negative or inconclusive. Some studies comparing the sensitivity and specificity of US versus X-ray showed that US is more sensitive than X-ray, because the sonographic changes are present at earlier stages, in comparison to typical X-ray signals (56, 57). PDUS allows the visualization of the characteristic aspects for the diagnosis of gout (such as the “double contour signal”, defined as an irregular linear hyperechoic layer on the superficial margin of the anechoic hyaline cartilage and parallel to the bone cortex, without a posterior acoustic shade, the bright hyperechoic foci, referable to microtophi and hyperechoic areas in synovial tissue, and tophi within joints, soft-tissue structures such as tendons, ligaments and bursae, and also invading into bone) as well as joint effusion, synovial hypertrophy and hypervascularity. PDUS allows the visualization of the changes in the inflammatory process of gout. The evaluation of gout by PDUS demonstrates increased flow in the acute phase of the podagra crisis, and generally, PD shows no flow when the patient is out of the gout crisis, but it has been observed that painful periarticular areas in patients with a known diagnosis of gout can exhibit hyperechoic tophi and flow with PD, even without the classic signs of crisis (58). Furthermore, PDUS has been demonstrated to be useful in the evidence that synovitis is frequently present in osteoarthritis. Despite osteoarthritis traditionally being viewed as a non-inflammatory disease, studies have shown a high prevalence of synovitis in both non-erosive and erosive osteoarthritis. The difference in prevalence of power Doppler activity across non-erosive and erosive osteoarthritis suggests more “active” synovitis with more neoangiogenesis in erosive osteoarthritis (59, 60).

Several methodical papers have confirmed the potential of PDUS for the measurement of disease activity in patients with RA (61-64). Different semiquantitative systems have been proposed for scoring intra-articular power Doppler signals. The most frequently used are semiquantitative scoring systems that score the Doppler information on a scale of 0–3 (0, no intra-articular PD signal; 1, mild: singles vessel signal; 2, moderate: confluent vessel signals in less than half of the synovium area; 3, severe: vessel signals in more than half of the synovium area), with increasing scores indicating increasing amounts of color in the synovium (65, 66) (Figure 4). This system is easily applicable in clinical practice and clinical trials, and is reliable and responsive to therapeutic interventions.

Although PDUS is useful for the assessment of synovitis, it is a flexible and sonographer-dependent examination and settings of US machines and the scanning technique of the sonographer can greatly influence the visualization of synovial vascularity and reproducibility is a major problem (67). Several studies demonstrated that appropriate training in scanning technique and reading of PDUS images could improve and stabilize the reproducibility and reliability of scor-
ing trials (68-71). A quantitative method to measure pixel counts of synovial vascularity in the region of interest has been proposed (72, 73).

More recently in the MEDUSA project, a computer aided diagnostic system that supports an assessment of synovitis severity, has been proposed (74). Quantitative assessment of synovial Doppler signal has the advantages of being more objectives than semiquantitative assessment. Schmid et al. (75) compare subjective estimation with grading system for synovial PDUS (using the semi-quantitative score from 0 to 3 proposed by Szkudlarek et al. and Naredo et al.) and computerized quantification of synovial perfusion in active RA and concluded that electronic measurement of the maximum colour fraction in the synovium may replace semi-quantitative scores, and is more sensitive to evaluate the change for follow-up RA trials (65, 76, 77). In addition, PDUS may be considered an important outcome measure, in fact high vascularity of synovitis and persistent synovitis, evaluated by PDUS, even in the absence of clinical symptoms, are predictive markers for the development of severe erosive RA (78, 79). In patients with RA in clinical remission, the presence of a power Doppler signal at the wrist and metacarpophalangeal joints was found to be associated with risk of relapse and structural progression (80). Other studies detected radiographic evidence of newly developed bone erosions in RA patients in persistent remission, suggesting that a residual subclinical inflammation may be missed using only clinical and laboratory data and therefore the use of imaging techniques has been claimed to state true disease remission (81, 82).

Vreju (83) scanned the metacarpophalangeal joints of twenty-four patients with RA in clinical remission according to EULAR criteria and found a positive correlation between the US bone erosions and PDUS signs of subclinical synovitis. Therefore this data support the hypothesis that in patients with RA joint damage and bone erosions are considered the result of persistent synovitis and that bone erosions may occur also in patients achieving clinical remission. Brown et al. (82), in asymptomatic RA patients, using ultrasonography, observed synovial hypertrophy and abnormal power Doppler signal in 73% and 43% of patients, respectively, while MRI revealed synovitis and bone marrow oedema in 96% and 46% of these patients. Therefore, its use in the clinical setting of remission may reveal active vascularized synovium and therefore influence therapeutic decision-making.

PDUS can help to differentiate patients with aggressive disease in early RA, allowing the targeting of expensive therapies to those with a poor prognosis (84). Many longitudinal studies have demonstrated the ability of PDUS to assess changes in synovial blood flow induced by different treatments, including intra-articular corticosteroid injections, systemic corticosteroid therapy, synthetic and biologic DMARDs and therefore it could be considered a useful tool for therapy monitoring in patients with chronic arthritis (85-89). In our previous study we evaluated 20 patients with clinically active synovitis of a small joint unresponsive to systemic drug treatment. They underwent a sonographic guided intralesional injection with triamcinolone acetonide. Joint cavity widening and PD signals were evaluated and graded on a semi-quantitative scale ranging from 1 to 4. Clinical and sonographic follow up examinations were carried out 2 weeks after the injection with triamcinolone acetonide. The results of this study support the view that US and PDS may be regarded as useful adjunctive tools for assessing short-term soft tissue changes after intra-articular injection treatment with triamcinolone acetonide in the small joints of patients with chronic synovitis (90).

**Contrast-Enhanced Color/Power Doppler**

An ultrasound contrast agent consists of a suspension of relatively uniform, highly reflective, stabilized gas-filled spheres, which enhance the Doppler signal, increasing its sensitivity for detection of low velocity blood flow at the level of the small vessels.

In contrast to MRI contrast medium, the US contrast agent stays inside the lumen of the vessel and does not diffuse in the extraarterial tissue. No extravasation into the surrounding tissues is found, indicating that ultrasound contrast medium acts as an intravascular contrast agent.

First-generation ultrasound contrast agents, for example, galactose palmitic acid (Levovist®, ScheringAG, Berlin, Germany), increase the sensitivity of
the color signals. The more recent type of US contrast agents consists of stabilised microbubbles of a sulphur hexafluoride gas (SonoVue®, Bracco, Milan, Italy). They provide a higher sensitivity and allow the delineation of weak intraarticular blood flow. This method depicts the blood flow in a grey scale image that provides only inaccurate information on the anatomic structures around the perfused areas (Figure 5).

The use of contrast-enhanced US (CEUS) seems to provide significantly higher sensitivity than PDUS in the identification of abnormal vascularization in joint inflammation, allowing a more exact measurement of the synovitis, as well as a quantitative assessment of inflammation by using the analysis of time-intensity curves. Analysis of time-intensity curves in a region of interest allows quantification of synovial inflammation. The area under the curve, the slope of the ascending and descending curve, measurement of flow rate, assessment of vascular volume, and estimate of mean velocity are all aspects allowing detailed evaluation of synovial inflammation.

In 2005 in a multicenter study of the International Arthritis Contrast Ultrasound study group, comparing contrast-enhanced ultrasound versus gray scale and power Doppler ultrasound for detection of joint vascularity in patients with rheumatoid disease, a total of 113 joints were examined and contrast-enhanced ultrasound was found to improve assessment of vascularized synovial proliferation and the differentiation of active synovitis from inactive intra-articular thickening (91). A number of other studies have investigated contrast-enhanced power and/or color Doppler ultrasound in the assessment of synovitis (92, 93). Most of these have been performed in patients with RA and showed that contrast agents amplify detection of the color signal and facilitate differentiation between active and inactive synovitis (94, 95). Other studies reported that contrast enhanced color Doppler US significantly improves the detection of intra-articular vascularization (94) and may increase the detection of even minor perfusion (96). There is evidence showing that administration of a contrast agent significantly improves the detection of color and power Doppler signals at the knee and finger joints in patients with RA (94, 97).

Previously, we employed PDS with ultrasound contrast agent to evaluate the degree of vascularization of the synovial membrane of the knee of 41 patients with RA, as well as to correlate the values of the area under the time–intensity curves obtained after administration of Levovist to the clinical and laboratory findings of disease activity (98). The results showed that the area under the curves (AUC) correlated with the degree of knee inflammation, being significantly higher in patients with clinically active synovitis compared with those with inactive synovitis. In addition, the mean value of the area under the curves was weakly correlated with the number of swollen joints, whereas it showed a stronger correlation with the composite indexes of disease activity, such as disease activity score and chronic arthritis systemic index. Therefore, the development and introduction of microbubbles ultrasound contrast and new ultrasound images may be considered a very promising technique for evaluating and measuring the degree of knee joint inflammation in RA and the time-intensity curves may have a clinical potential for both diagnostic and therapeutic purposes (98). In this regard, PDS with an intravenous ultrasound contrast agent has been shown to be able to detect changes in synovial perfusion after intra-artic-
ular steroid injection and may be an additional useful method in the evaluation of the therapeutic response.

In our previous study, to evaluate the ability of PDUS with ultrasound contrast agent to assess the synovial perfusion changes induced by intra-articular steroid injection therapy, we studied eighteen RA patients with a history and signs of active knee synovitis. Gray-scale US and PDS with an intravenous ultrasound contrast agent (Levovist) examinations were carried out before and 3 weeks after the intra-articular steroid injection. The calculation of the time–intensity curves provided a quantitative estimation of the synovial perfusion. The comparison between baseline and follow-up median values of the AUC showed a statistically significant reduction of blood flow in synovial pannus after intra-articular steroid therapy. These data confirmed the ability of PDUS with ultrasound contrast agent to evaluate the therapeutic response (99).

The main issues limiting the use of ultrasound contrast media are the relatively high running costs involved, the relatively short duration of examination, and the need for optimally designed bubbles for near-field investigation at higher frequencies.

**Magnetic Resonance Imaging (MRI)**

MRI is a multiplanar, non-ionizing and non-invasive imaging technique and is considered the reference imaging modality in the assessment of soft tissue inflammation, in form of synovitis, tenosynovitis, enthesitis and bursitis, as well as joint damage (in terms of bone erosion, cartilage loss, and tendon rupture) in chronic arthritis (100-105). It has advanced our understanding of many types of arthritis, both with respect to inflammatory processes and articular damage. According to the Recommendation of the *Arthritis Subcommittee of the European Society in Musculoskeletal Radiology* (106), MRI allows the:

- assessment of peripheral joints for active inflammation in the form of effusion, synovitis, bone marrow oedema, as well as the subsequent structural lesions, such as articular surface damage and cortical bone erosions,
- assessment of inflammatory lesions and structural changes in the sacroiliac joints,
- assessment of inflammatory and post-inflammatory lesions of the vertebral joints, i.e. assessment of the inflammatory activity, aseptic spondylodiscitis, atlanto-axial/atlanto-occipital structural lesions,
- assessment of tenosynovitis and enthesopathic lesions,
- confirmation of clinical diagnosis based on imaging characteristics and/or location of lesions,
- qualitative, semi-quantitative and quantitative measurements of active inflammation and chronic joint damage.

As far as rheumatic diseases are concerned, MRI surpasses plain radiography and US with its ability to visualise the bone marrow involvement. Also, early inflammatory features within soft tissues (joints, tendons, sheaths and bursae, muscles) that are not seen on plain radiography in detail and are inaccessible to ultrasound (e.g. of the spine, sacroiliac joints) or their assessment in ultrasound is limited (e.g. hip and gleno-humeral joints) are well seen in MRI. Although clinical examination has been a cornerstone in identifying and monitoring disease progression in RA and PsA patients, MRI has been shown to be more sensitive than clinical examination for identifying synovitis (Figure 6). The more important indications for MRI in patients with musculoskeletal rheumatic diseases include early diagnosis of inflammation, confirmation of the presence of clinically active changes and post-inflammatory structural lesions, disease follow-up including monitoring of therapy response and identification of disease complications.

MRI can identify bone erosions earlier than conventional radiography and allows the evaluation of bone marrow edema/osteitis, due to the presence of an inflammatory infiltrate within subchondral trabecular bone, and synovitis, which may be important precursors to bone erosions in RA (107) (Figure 7). Signs of inflammation may be detected by MRI also in PsA, and findings such as synovitis, tenosynovitis and bone marrow oedema (BMO) document the presence of an inflammatory process, although not specific for PsA (108). In early PsA disease, MRI of wrists and hands detected diaphyseal BMO and/or enthesitis in more than 70% of PsA patients, whereas these features were absent in a matched group of RA patients (109, 110).
Given these properties, MRI has been proposed as a diagnostic tool for individuals with suspected inflammatory arthritis and has been proposed as a means to improve rheumatologists’ ability to diagnose early RA and predict which patients will likely develop progressive disease and thus should receive more aggressive treatment (111).

Currently its use is not extended to all affected patients due to long examination times, its elevated cost, limited availability, need for contrast medium to increase specificity, and contraindications in certain patients (112). In addition, MR images are in many cases non-specific and require differentiation from other pathologies manifested by the same spectrum of changes. The main indications for MRI in patients with musculoskeletal rheumatic diseases include (106):

- early diagnosis of inflammation in both soft tissues and bone marrow, before destructive lesions develop (cysts, erosions, cartilage damage);
- confirmation of the presence of clinically active changes and post-inflammatory structural lesions;
- quantitative assessment of synovitis;
- prognostic value in early RA and PsA;
- disease follow-up, including monitoring of therapy response.

**Diagnostic value of MRI in early diagnosis and synovial assessment**

There are two main ways in which MRI can assist the clinician in this respect. First, the presence of
subclinical synovitis can be confirmed, allowing for example, the patient with non-specific hand and/or wrist pain to be differentiated from the patient with true inflammatory synovitis. The second way by which MRI can assist in making a diagnosis of RA is by revealing erosions that comprise one of the seven ACR 1987 diagnostic criteria (113). Synovial thickening is the earliest pathologic abnormality in RA and it is secondarily responsible for bone and cartilage damage (114).

Studies comparing normal individuals with RA patients have shown that while minor synovial enhancement may be seen in normal wrists, significant thickening and inflammation of the synovial membrane is confined to those with inflammatory arthritis (115). Where there is a clinical diagnosis of RA, >90% have MRI evidence of synovitis and 70–80% have tenosynovitis (116). The synovial membrane, or synovium, which can be identified macroscopically as a connective tissue that lines normal joint cavities, bursae, and tendinous sheaths is usually too thin to be visible on MR images. The thickening of synovial tissue caused by the inflammatory process may be identified at MR imaging (117) and is also characterized by increased vascularity, which is a result of angiogenesis (118). MRI signs of synovitis include increased synovial volume, increased water content, contrast enhancement or a combination of them (119-121). The MRI data suggested that the level of synovial thickness was critical in determining the amount of bone damage. In fact, several studies have shown that synovial volume correlates with synovial inflammatory activity and with joint swelling and tenderness and is predictive of clinical disease activity (122-125).

The OMERACT group defines synovitis as an area in the synovial compartment with increased contrast enhancement whose thickness exceeds the width of the normal synovium (126, 127). Synovitis has intermediate to low signal intensity on T1-weighted images and high signal intensity on T2-weighted images, due to the increased water content.

The use of fat-suppressed T2-weighted MR imaging more clearly delineates disease extent. Synovitis and joint fluid are usually difficult to differentiate on unenhanced MR images; however, on T2-weighted images synovitis has a lower signal intensity than does joint effusion (128). The use of intravenous gadolinium-based contrast material is necessary to estimate the degree of synovial inflammation and for differentiation between active synovitis and fibrotic pannus (Figure 8). Fibrotic pannus, which is usually present in end-stage RA, appears relatively hypovascular after the intravenous administration of gadolinium-based contrast material. Sugimoto et al. (129) have shown that the “bilateral joint hyperuptake” criteria, evaluated through MR after the infusion of paramagnetic contrast (Gd-DTPA), increases the sensitivity of the ACR criteria for RA from 77% to 96%. The combination of this with positive biologic markers such as anti-citrullinated peptide antibodies or rheumatoid factor (RF), with the MRI parameters (symmetric synovitis, bone edema, erosions) has a sensitivity and a specificity for the detection of early RA of 82.5% and 84.8% respectively (130). Østergaard et al. (131) demonstrated that assessment of synovitis using the short tau inversion recovery (STIR) or T2 fat-saturated images is less accurate and reproducible than using T1-weighted post-contrast images.

Contrast-enhanced T1-weighted images are considered more sensitive and specific in the assessment of acute synovitis, which has been shown to enhance rapidly and intensely after the intravenous administration of gadolinium-based contrast material, unlike joint effusion, which does not enhance in the early phase. The delay between contrast administration and scanning is important as the volume of enhancing synovitis increases initially before stabilizing after about 4 min. After 6–11 min contrast reaches the synovial fluid, obscuring the synovium/fluid interface.

The use of fat suppression increases the contrast between the inflamed synovium and adjacent structures on contrast-enhanced T1-weighted images (132). Dynamic contrast enhanced MRI (DCE-MRI) involves the acquisition of sequential images in rapid succession every few seconds during and after the intravenous administration of contrast agent. This allows the time-course of the synovial enhancement to be analysed and measurements made from the enhancement curve are sensitive to various physiological parameters, including synovial perfusion and capillary permeability.

The region of interest (ROI) of inflamed synovium from which the enhancement curve is determined may be chosen in different ways. Then it is possible
to measure several parameters from the enhancement curve, that include the early enhancement rate, the maximum enhancement and the late or static enhancement. The early enhancement rate has been shown to correlate with erosions (133–135), erosive progression (136) and effects of treatment (137). There is a better correlation with histology (125) and response to treatment (138) than the static enhancement. The enhancement rate correlates with other imaging measures of synovial volume, erosion, vascularity, capillary permeability and metabolic activity. The rate and magnitude of synovial enhancement on sequential MR images after bolus intravenous injection of gadolinium have been shown to correlate with the histological severity of inflammation in the synovium and with clinical markers of disease activity (139).

Van de Sande et al. (140) showed that the shape analysis of DCE-MRI might have potential as a diagnostic biomarker in early arthritis patients. They observed a significantly higher percentage of Type 4 TIC shape (fast initial enhancement followed by a quick washout phase) in the RA patient group compared with the non-RA group. There is evidence showing correlations between perfusion imaging and histological synovial inflammation (125, 141). Vordenbäumen et al. (141) compared dynamic contrast-enhanced magnetic resonance imaging and histological synovitis of the second MCP joints in 9 RA patients. The re-
Results of this study demonstrated that synovitis of MCP joints measured by maximum enhancement on dynamic MRI strongly correlates to histological inflammation within the same joint.

These data underscore the validity of dynamic contrast-enhanced MRI for the assessment of the degree of synovitis in small joints. Relevant studies have mostly focused on the knee, where synovial tissue can be most readily obtained. König et al. (142) evaluated inflammation in the knees in 20 RA patients using dynamic enhanced MRI and compared these results with histological data obtained from biopsy of the synovial membrane performed arthroscopically or operatively in 12 patients. Their preliminary findings revealed hyperintense signal on T2 weighted images, correlating with “remarkable” enhancement on post contrast-enhanced T1weighted images in three patients, and this appearance matched hypervascular pannus in a histological assessment. In contrast, hypointense lesions on MRI correlated with histologic evidence of fibrous pannus with a “burnt out” appearance (117).

Gaffney et al. (143), compared the intensity of rheumatoid synovitis in the knee, measured using the initial rate of enhancement on postcontrast MRI scans, with a score for inflammation calculated from multiple synovial biopsy samples taken from the suprapatellar bursa. They found a strong correlation between the enhancement-rate and a composite histologic inflammatory score quantifying polymorphonuclear cellular infiltration, hyperemia, and fibrin deposition. Similar results were obtained by Tamai et al. (144), who compared the enhancement-ratio with a histologic score for inflammation on synovial biopsy specimens taken from the knee in 10 patients. In their study, enhancement post-contrast was greater in regions with a high degree of fibrin exudation, cellular infiltration, villous hypertrophy, vascular proliferation, and infiltration by granulation tissue but not in regions affected by fibrosis. A similar work was done by Østergaard et al. (124) on the knees of 17 RA patients and 25 with osteoarthritis (OA). The volume of synovial membrane was determined using a manual outlining method to determine its boundaries on consecutive slices, and this surrogate measure of synovitis was then compared with a histologic assessment of inflammation, again from biopsy specimens taken from the knee arthroscopically.

A strong correlation was found between this MRI synovial volume score and a composite histologic inflammation score. Synovial membrane volumes were also shown to be higher in RA and PsA than OA knees. Even though MRI will probably only rarely be able to assign specific diagnoses alone, it can be a very useful addition to the differential diagnostic process. MRI may be valuable for diagnosing specific arthritides, including early RA, in patients with undifferentiated arthritides, but the sensitivity and specificity, and so on, of MRI are not yet known. The few studies that employ MR for the differential diagnosis of RA with other rheumatic diseases, such as systemic lupus erythematosus, Sjögrens Syndrome or PsA don’t find statistically significant differences regarding synovitis, erosions, or tendinous alterations (145, 146). The different parameters evaluated by MRI are employed as predictive markers of erosions, allowing the clinician to select patients with a worse prognosis and establish a rapid and aggressive therapeutic strategy. Cimmino et al. (146) using dynamic MRI of the wrist, observed that the rate of increase in enhancement following contrast injection did not differ between PsA and RA patients when they were matched for disease activity, but in both groups it was higher than in normal control individuals. The authors concluded that dynamic MRI cannot be used diagnostically to differentiate PsA from RA. Others have measured PsA synovitis on static magnetic resonance scans. Savnik et al. (147) noted that the volume of synovial membrane was increased but did not change significantly over 1 year, contrasting with RA patients, in whom it fell in response to therapy. Jevtic et al. (148) described MRI of the finger joints in a group of patients with PsA, three with Reiter’s syndrome and with RA. Although in some PsA patients synovitis was observed to conform to a typical rheumatoid pattern, in others there was inflamed tissue extending far beyond the joint capsule, involving neighbouring structures such as thickened collateral ligaments and surrounding periarticular soft tissue. McGonagle and colleagues (149) went on to describe in greater detail the MRI features of enthesitis that may be seen in association with synovitis in PsA, and postulated that true PsA can be distinguished from RA with concomitant psoriasis on these grounds.
Although histopathological studies have suggested that inflamed synovial membrane of PsA differs in certain subtle ways from rheumatoid synovium with less lining layer hyperplasia, more subsynovial oedema and a greater number of synovial vessels per square millimetre, on MRI, PsA synovitis appears indistinguishable from that of RA (150). In an other study, Cimmino et al. (151) studied 8 patients affected by acute gout arthritis involving the wrist and MRI was performed during the acute attack. They found a high frequency of synovitis and bone lesions of the wrist, but they were difficult to differentiate from those of RA.

Synovitis is also a feature of OA, and angiogenesis, inflammation, and innervation are important processes in the pathophysiology contributing to the symptoms and radiological progression of OA. The different pathogenesis of OA and RA may reflect a difference in the mechanisms of inflammation and angiogenesis, and this could possibly be expressed in DCE-MRI. However, only a few studies have evaluated synovitis in OA using MRI and these studies have mainly estimated the volume of knee joint synovitis (124, 152). Kirkhus et al. (153) to investigate the utility of the DCE-MRI to differentiate between finger joint synovitis in established OA and RA, studied 19 patients (11 with RA e 8 with OA) and 6 healthy individuals without any symptoms or known disease. All subjects underwent DCE-MRI of one hand and from the signal intensity curves, the three parameters: endothelial transfer constant, elimination rate constant from extracellular space back to plasma and elimination rate constant from plasma by renal excretion, were calculated. The results of this study showed that DCE-MRI with derived pharmacokinetic parameters can provide useful information in differentiating synovitis in hand OA from synovitis in RA, and it is also possible that the method can be used to estimate the degree of synovial inflammation.

MRI synovitis is a reasonable indicator of true synovial inflammation, but changes resembling mild synovitis or small bone erosions are occasionally found in the MCP and wrist joints of healthy controls. Ejbjerg et al. (115) studied 28 healthy individuals using contrast-enhanced MRI of the wrist and MCP joints. Low grade of synovitis was found in 9% of the MCP joints and in 10% of the wrist joints, but almost half of these changes were observed in 3 subjects who had elevated CRP levels and therefore could possibly have had subclinical inflammation. Dynamic MRI revealed only minimal synovial enhancement compared with levels in RA patients that were 30-fold higher. Furthermore, lesions suggesting erosions in healthy individuals are usually small, single and do not present gadolinium uptake. The results of this study give an insight into the specificity of MRI synovitis and indicate that while low-grade enhancement can occur in normal joints, most RA joints exhibit much greater degrees of membrane thickening and enhancement, which is strongly indicative of disease.

Quantitative assessment of synovitis

Quantifying total synovial volume (hypertrophy) and the synovial volume could be a marker for disease activity (122, 154-156). Synovitis can be assessed with quantitative or semiquantitative methods. With quantitative methods, inflammatory activity can be estimated by quantifying the volume of synovial tissue or evaluating the increase in early synovial signal intensity at dynamic contrast-enhanced MR imaging. The volume of inflamed synovium can be quantified on contrast-enhanced MR images with use of manual or computer-assisted techniques. Visualization of the inflamed synovium for volume measurement requires intravenous contrast to reliably exclude other tissues. The analysis of gadolinium-enhanced MRI can provide objective information regarding the severity of inflammation. DCE-MRI is an alternative quantitative method to measure synovitis by administering gadolinium-based contrast agents (GBCA) intravenously and collecting sequential images of the joint in a time course (157). The enhancement curve generated by DCE-MRI can be used to estimate physiological parameters, such as $K_{trans}$, the volume transfer constant of GBCA between blood plasma and the synovium. This endpoint is related to capillary permeability and vascularity in the synovium, and correlates strongly with histological measures of inflammation (158).

DCE-MRI has previously been used to evaluate synovial inflammatory activity in patients with RA in the knees showing that the steepness of the dynamic curves correlates better with histological synovial vas-
cularity and inflammatory cell infiltrate than measures of the corresponding post-contrast-enhancing synovial volumes (124, 159). The steepness of the dynamic curve in the synovium has also been shown to be very sensitive to change after intra-articular steroid injections in knee joints with arthritis (160-162) and recently the same observation was published for BME in wrists of RA patients starting anti-TNF-a treatment (163).

In RA the most frequently used method is the OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) (126, 163), which allows assessment of synovitis in three wrist regions: the distal radioulnar joint; the radiocarpal joint; and the intercarpal, carpometacarpal, and metacarpophalangeal joints. Joints are assessed on a scale from 0 to 3. A score of 0 is normal, whereas scores of 1 (mild), 2 (moderate), or 3 (severe) reflect the presumed maximum volume of enhancing tissue in the synovial compartment (126). In table 1 definitions, basic sequences, anatomic planes and areas and RAMRIS System Scores as proposed by OMERACT Task Force are reported.

Both RAMRIS and DCE-MRI are valid measures for detecting treatment effect, but they are not interchangeable and may reflect somewhat different biological processes related to joint inflammation. Further, scoring MRI at the wrist is a complex task, requiring a detailed knowledge of the 3-dimensional anatomy of the carpal bones and joints as well as an understanding of the different sequences used, the signal characteristics of the tissues being imaged, and potential sources of error that are intrinsic to the modality itself. The latter include phenomena such as partial voluming, where signal from two sharply contrasting areas is “averaged” in the intervening zone, homogeneity of fat saturation, and variations in Gd-DTPA uptake, which need to be interpreted by a trained reader. This makes MRI scoring considerably more difficult than scoring radiographs to assess joint damage (164).

Cytéval et al. (165) developed a simplified MR imaging scoring method (Simplified Rheumatoid Arthritis Magnetic Resonance Imaging Score [SAMIS]) for assessing wrist and metacarpal joint damage in RA. SAMIS assessed only one hand and was based on the radiographic Simple Erosion Narrowing Score, thus reducing the number of study areas from 116 to 36. Erosions were scored with a scale from 1 to 10. Edema and synovitis were, respectively, scored on scales from 0 to 1 and 0 to 2. The simplified score is closely correlated with the MR imaging score standard RAMRIS, requires less examination time than RAMRIS (5 minutes vs 20 minutes) and shows good or excellent intra- and interobserver agreement (165).

The international MRI in arthritis group of OMERACT has developed the Psoriatic Arthritis Magnetic Resonance Image Score (PsAMRIS) for the evaluation of inflammatory and destructive changes in PsA hands (166). This is the most validated assessment system available and has a documented good intrareader and inter-reader reliability for status scores of all parameters (167). The responsiveness of the PsAM-

Table 1. Definition, Basic Sequences, Anatomic Planes and Areas, and RAMRIS System Scores as Proposed by the OMERACT Task Force*

| Definition            | Sequence Planes | Anatomic Areas | Score/Total |
|-----------------------|-----------------|----------------|-------------|
| Synovitis             | T1 before and after axial contrast | Radiocarpal, intercarpal | 0.3/0.21 |
| Bone edema            | 2 fat suppression T or STIR, coronal | 2 to 5th MCPI, head of P1, 8 carpal bones, bases of 1st to 5th MCP, distal radius and ulna | 0-3, 0: no bone edema; 1: bone edema that occupies 1% - 15% of bone; 2: bone edema that occupies 16% - 40% of bone; 3: bone edema that occupies 41% - 100% of bone; 4: bone edema that occupies more than 100% of bone |
| Erosions              | T1 (1)/axial and coronal | 2 to 5th MCPI, head of P1, 8 carpal bones, bases of 1st to 5th MCP, distal radius and ulna | 0-100/0-69 |

* In the case of long bones, it is measured from the joint surface to 1 cm depth; carpal bones are evaluated as a whole.
(1) The administration of contrast with gadolinium allows for the evaluation of erosion activity due to the presence of inflammatory pannus.
MCP indicates metacarpophalangeal; MCPI, metacarpal; 1P, first phalanx.
RIS was excellent for tenosynovitis (hand), synovitis (foot), and periarticular inflammation (hand and foot) (168).

**Prognostic value of MRI**

The ability of MRI to assess both detailed changes in bone structure (i.e. erosions) and synovial inflammation combined with its multiplanar capability is well established (169, 170). MRI can identify bone erosions earlier than conventional radiography (171) and can detect bone marrow edema and synovitis, which may be important precursors to erosive disease (172) (Figure 9). Given these properties, MRI has been proposed as a diagnostic tool among individuals with suspected inflammatory arthritis and as a prognostic tool among those with known RA. The ability to predict aggressive disease when a patient first presents is an important clinical goal, because this would allow potent and potentially toxic disease-suppressing medication to be targeted to patients who are most in need. This predictive ability has become even more desirable from a medico-economic viewpoint with the advent of anti–tumor necrosis factor alpha therapies, which have powerful antierosive effects (173).

Substantial efforts have been exerted to identify patients with poor prognosis at the time of diagnosis. Suter et al. (174) performed a systematic review of published studies assessing the diagnostic and prognostic capability of MRI findings in undifferentiated inflammatory arthritis and early RA, respectively. It found that are currently inadequate to justify widespread use of this technology for these purposes, although MRI bone edema may be predictive of progression in certain RA populations (175, 176). Duer-Jensen et al. (177) in a large, prospective follow-up study of patients with undifferentiated arthritis (UA), found the OMERACT MRI summary score for bone edema in the MTP and wrist joints to be an independent predictor of future development of RA. These finding that bone edema is the most important MRI predictor of the subsequent disease course in UA is consistent with the fact that several studies in patients with early RA have shown that bone edema revealed on MRI is the most important predictor for future progression of erosions (172, 178-180). The mechanism underlying the association between bone edema and erosion remains to be determined, but bone edema in this context could represent an intraosseous cellular infiltrate capable of eroding cartilage and bone from the subchondral aspect.

![Figure 9. Rheumatoid arthritis. (A, B, C) Coronal STIR images showing joint effusion in the carpal joints, carpal-metacarpal joints and the distal radio-ulnar joint. Bone edema of the carpal bones and the metacarpal bases, with multiple erosion involving the carpal bones can be observed. An erosion of the head of the third metacarpal can be also observed. (D, E, F) Axial STIR images showing tenosynovitis of the extensor carpi ulnaris tendon, of the extensor digitorum and indicis tendons, of the extensor pollicis brevis and abductor pollicis longus tendons. (F) Axial STIR images showing tenosynovitis of the flexor superficialis and profundus tendons. (G) Coronal Gradient T1 image showing multiple erosions in the carpal bones](image-url)
Evidence for such an infiltrate has been described in animal models of RA, in which TNF-responsive mesenchymal cells were identified within enlarged bony canals connecting bone marrow to synovium (181). This is consistent with MRI evidence indicating that bone oedema is a pre-erosive change, increasing the risk of bone erosion more than 6-fold after 6 yrs according to one study (182). Haavardsholm et al. (183) and Hetland et al. (184) reproduced these findings at 1 and 2 years, respectively. Bone edema thus seems to be a very important predictive feature in both RA and pre-RA and MRI scans performed at the first presentation of RA can be used to help predict future radiographic damage (107). As in RA, the histopathological correlate of MRI bone oedema has not been defined in PsA, but Bollow and coworkers (185) found some evidence of osteitis in subcortical bone in their biopsy study of sacroiliac joints in SpA patients (including two with PsA).

To the rheumatologist, synovitis may appear to be the most important indicator of aggressive disease. In fact, the MRI evidence disputes this and data from the CIMESTRA study failed to show MRI synovitis to be an independent predictor of erosions at all. However, a number of groups have shown that a high score for all MRI disease activity and damage features combined (including synovitis, bone oedema, tenosynovitis and erosions) is the best indicator of poor prognosis (186, 187). Therefore, there was marked variation among studies regarding the MRI classification criteria used to diagnose RA, considerable variability in methodological quality and overall, sensitivity and specificity of MRI findings varied broadly (range 20–100% for sensitivity and 0–100% for specificity), even for comparable MRI definitions of RA.

The utility of MRI to predict radiographic progression among individuals with no baseline radiographic erosions or to predict clinical outcomes such as remission remains undefined. The increased sensitivity of MRI for erosions that arise from the direct paired-bone comparisons is evident (188–190), but must be tempered by the increased false-positive rate for MRI erosions in healthy controls (115, 191). Conaghan et al. (192) consider that the intensity of gadolinium uptake, that is, the synovial volume reinforced after paramagnetic contrast infusion (synovitis) and total synovial volume (hypertrophy), are predictors of erosions at the beginning of the disease.

Additionally, the quantitative measurement of the synovial volume that is responsible for the uptake of gadolinium in MRI of the manual measurement of the total volume (hypertrophy) seem to be disease activity markers and are correlated with progression of the erosions (147, 193). Studies are warranted on the prognostic value of MRI findings in PsA.

The utility of MRI to monitor response to therapy

A number of groups have investigated MRI features as ‘imaging biomarkers’ for measuring therapeutic responses (Figure 10). Changes in MRI synovitis were first assessed at the knee by Østergaard et al. (194) who demonstrated a 50% reduction in synovial membrane and effusion volumes during the week after intra-articular steroid injection. The modern treatment strategy involves early and aggressive treatment with frequent clinical follow-up aiming at reaching a target of clinical remission in patients with early RA and at least a state of low disease activity in patients with longstanding RA (195). This treat-to-target strategy

![Figure 10. Juvenile idiopathic arthritis. Sagittal T1 fat-sat images of ankle. (A) Pre-gadolinium and (B) post-gadolinium images showing synovitis of the talo-calcaneal joint at baseline and (C, D) after 3 months of treatment illustrating a marked reduction of synovitis](image-url)
has been shown to slow the destructive progression and prevent functional loss (196, 197). However, it has been demonstrated that, despite optimal control of clinical and laboratory findings, erosive disease progression may continue to progress for subsets of the disease population (20-30% of patients who reach the treatment target of clinical remission still show progressive erosive joint damage) (189, 198). These data suggest that diagnostic imaging may complement pharmacotherapeutic decision-making (199, 200).

Early pharmacologic treatment of RA with conventional and biologic disease-modifying anti-rheumatic drugs (DMARDs) has proven to improve clinical (201-203) and radiological outcomes (204). Zikou et al. (205) evaluated the volume of synovial pannus in 13 patients pre- and post-adalimumab and found this to fall by 86% after 1 yr, correlating with other inflammatory markers. Haavardsholm et al. (206) showed a combined MRI inflammation score incorporating synovitis, tenosynovitis and bone oedema to be the most sensitive measure of response to anti-TNF agents.

MRI depicts the pathological changes in all tissues involved in RA and shows greater sensitivity in detecting inflammatory and destructive changes than both clinical examination and x-ray (207, 208). Haavardsholm et al. (206) has shown that MRI measures of inflammation provide superior responsiveness to conventional measures of disease activity in patients with RA treated with anti-TNFα medication. This superior sensitivity of MRI compared to conventional clinical examinations and radiographs, combined with the knowledge that MRI detected BME is a predictor of subsequent radiographic progression (175, 176) has generated the hypothesis that adding MRI to the conventional clinical and laboratory examinations and intensifying treatment in the presence of subclinical MRI-BME will reduce radiographic erosive progression and improve the patient’s functional level. The use of MRI as a treatment guide may be valuable in individualizing the treatment, so patients assessed as being at high risk of erosive progression can receive appropriately intensive treatment so disease progression can be avoided. Further, MRI measures as a structural end point in a clinical trial setting would impact the efficiency of the study design.

**Whole-body MRI**

Whole-body MRI is a novel imaging method, which allows MRI of the whole body in one scanning session, but at the cost of lower image resolution than conventional MRI.

With its comprehensive examination, whole-body MRI was first introduced in the specialties of oncology (209) and angiography (210). However, it may also prove useful in systemic musculoskeletal disorders, such as SpA, in the evaluation of both axial and peripheral abnormalities, including enthesitis (211).

Whole-body and conventional MRI showed a very good correlation for the detection of inflammatory lesions in the SI joints in patients with established and active SpA. Whole-body MRI is a fascinating new imaging modality also for RA. Using this technique most relevant joints can be assessed for synovitis, bone marrow oedema and erosions, as well as axial and enthesial pathology. The major drawback with the technique has been its insufficient resolution, notably in peripheral joints, which are frequently affected in these patients. So much work is necessary to improve and evaluate this technique.

Whole body MRI is frequently used in the pediatric field, both for the assessment of patients with juvenile idiopathic arthritis, but also for other diffuse musculoskeletal disorders. Whole-body MRI for evaluation of juvenile idiopathic arthritis is advantageous in that it allows for assessment of both disease activity and extent (Figure 8). Studies in the pediatric population are limited, but whole-body MRI has been shown to be superior to clinical examination in detecting arthritis in the hips, sacroiliac joints and spine (212). Consequently, whole-body MRI may play an important role alongside clinical exam and radiography as an objective tool for assessing active disease activity and guiding therapy in juvenile spondyloarthropathy patients. However, a recommendation to use whole-body instead of conventional MRI in daily routine seems to be premature. Further studies need to address the comparative performance for assessing inflammatory lesions in the spine and the clinical relevance of the additional information on inflammation in the anterior chest wall and the hip and shoulder girdles. Complementary to analyzing status scores, the validation
process of whole-body MRI needs to also compare responsiveness and reliability of change scores.

Conclusion and future application

US and MRI can be used both in clinical practice and clinical trials, for multiple purposes, including establishing or confirming a diagnosis of inflammatory joint disease, determining the extent of the disease, monitoring change in inflammation and structural damage, assessing therapeutic efficacy and potentially prognostication.

Within the field of imaging in inflammatory arthropathies, large and exciting advances have been made during the last decade. However to achieve these goals, standardisation and validation of US and MRI are required to ensure accurate diagnosis, reproducibility and reliability. The introduction of volumetric probes (VP), with the automatic acquisition of three-dimensional (3D) data sets, allows for sensitive, rapid, and less operator-dependent acquisition of Doppler images in patients with chronic inflammatory arthritis. Such probes have a transducer inside, which moves electronically when the operator presses the acquisition button, and acquires all the echoes under the footprint of the volumetric probe. The stored 3D datasets can be explored using a dedicated software that generates sectional views of the three main planes (longitudinal, transverse and coronal, which share only one point) and 3D reconstructions. Both B-mode and CD or PD Doppler mode can be used in volumetric scanning. 3D PDUS has been proven to provide a good imaging reproduction of the synovial blood flow representing a complete vascular tree inside and on the verge of the synovial tissue (213). Naredo et al. (214) suggest that volumetric PDUS can be used in multicenter open-label cohort studies on patients with RA. The added value of this technology over conventional US could be to minimize assessment biases and reduce acquisition variability. 3D US techniques have been tested, particularly in RA, for their capacity to record the full extent of inflammation within a joint and to visualize the size and surface appearance of erosive lesions. In terms of sensitivity for the detection of synovitis and bony lesions, there is good to excellent correlation between results from this method and those from two-dimensional US (215). Therefore, 3D imaging is predestined to generate a more precise quantification of the vascularity and thereby affords the benefit of detecting small changes in the acquired volume in the monitoring of clinical and therapeutic strategies (215). The major disadvantage of 3D ultrasonography include the long image-acquisition time, the long size of the 3D dataset, which depends on the area of the probe footprint, and the static feature of the acquired images, which leaves the interpretation of imaging findings without the advantages provided by dynamic examination (216).

MRI is increasingly used in RA trials and practice. The capacity of MRI to detect early changes in soft and synovial tissue, bone and extraarticular makes this technique a useful tool in the study of RA. Possible future applications of MRI would be to examine the capacity of this technique to allow for the diagnosis of different inflammatory arthropathies based on anatomical localization of the structural lesions or the type of lesion, such as enthesis in the case of SpA (217). On the other hand, knowing the sensitivity and specificity of MRI as a diagnostic or classification criteria at the beginning of the disease, and lastly, the capacity of this modality to help in the selection of patients with worse or better prognosis or even as responders to therapy or not. In recent years MRI have increasingly been used as outcome measures in clinical trials of RA. Several studies have shown that MRI measures of synovitis, tenosynovitis, bone marrow oedema and erosions are valid and reliable, but less is known about the responsiveness of these measures during an intervention with a potent therapeutic agent (218, 219).

The technical advances in the development of equipment of dedicated MRI, with a larger resolution for imaging and even portability, new technological advantages such as the introduction of 3D MRI sequences with isotropic voxels, which allows for the multi-planar reconstruction permits significant reduction of scanning time without loss of image quality, as well as the adequate training to interpret results, are hopeful proposals for the application of MRI in the diagnosis, follow-up and prognosis in patients with inflammatory arthropathies. A simplified MRI volumetric data acquisition may provide gross estimates of disease activity when the threshold is set properly.
Nonetheless, there are still many questions and more studies are needed to allow for some answers to these and other questions.

**Practice points**

- US is a non-invasive, reproducible, non-radiating, and relatively inexpensive technique used to detect, assess, and quantify both the inflammation of joints and structural damage caused by a variety of rheumatic diseases.
- PDUS is more sensitive than clinical examination in detecting inflammation in joints, tendon sheaths, tendons, entheses in patients with chronic inflammatory arthritis and allow monitoring of disease activity.
- The use of CEUS seems to provide significantly higher sensitivity than PDUS in the identification of abnormal vascularization in joint inflammation, allowing a more exact measurement of the synovitis, as well as a quantitative assessment of inflammation by using the analysis of time-intensity curves.
- MRI is a sensitive, accurate, non-invasive tool that allows simultaneous assessment of all the components of diarthrodial joints and offers the rheumatologist a chance to visualize joint inflammation as well as damage.
- MRI is proving to be a useful tool with which to investigate disease processes in inflammatory arthritis such as RA and has the potential for clinical use in determining the prognosis and targeting aggressive therapy to patients with the most destructive disease.
- Whole-body multi-joint is MRI allows a ‘snapshot’ of inflammation in systemic musculoskeletal disorders, such as spondyloarthritis, in the evaluation of both axial and peripheral abnormalities, including enthesitis.
- Future research in established and new MRI methods will increase the value of MRI to diagnose, monitor, and establish a prognosis in inflammatory arthropathies.

**References**

1. Weber AJ, De Bandt M. Angiogenesis: general mechanisms and implications for rheumatoid arthritis. Joint Bone Spine 2000; 67: 366-83.
2. Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxford) 1999; 38: 103-12.
3. Harris ED, Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-89.
4. Szkuularek M, Narvestad E, Klarlund M, Court-Payen M, Thomsen HS, Ostergaard M. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthritis Rheum 2004; 50: 2103-12.
5. Scheel AK, Hermann KG, Ohnrdorf S, Werner C, Schirmer C, Detert J, Bollow M, Hamm B, Muller GA, Burmester GR, Backhaus M. Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger joints. Ann Rheum Dis 2006; 65: 595-600.
6. Spadaro A, Lubrano E. Psoriatic arthritis: imaging techniques. Reumatismo 2012; 64: 99-106.
7. Caranci F, Brunese L, Reginelli A, Napoli M, Fonio P, Briganti F. Neck Neoplastic Conditions in the Emergency Setting: Role of Multidetector Computed Tomography. Semin. Ultrasound CT MRI 2012; 33: 443-448.
8. Naredo E, Aguado P, De Miguel E, Uson J, Mayordomo L, Gijon-Banos J, Martin-Mola E. Painful shoulder: comparison of physical examination and ultrasonographic findings. Ann Rheum Dis 2002; 61: 132-6.
9. Kane D, Balint PV, Sturrock RD. Ultrasonography is superior to clinical examination in the detection and localization of knee joint effusion in rheumatoid arthritis. J Rheumatol 2003; 30: 966-71.
10. Zappia M, Castagna A, Barile A, Chianca V, Brunese L, Pouliart N. Imaging of the coracoglenoid ligament: a third ligament in the rotator interval of the shoulder. Skelet Radiol 2017; 46: 1101-1111.
11. van Steenbergen HW, van Nies JA, Huizinga TW, Reijners M, van der Helm-van Mil AH. Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody-negative arthralgia patients at risk for rheumatoid arthritis. Arthritis Res Ther 2014; 16: R92.
12. Li X, Liu X, Du X, Ye Z. Diagnostic performance of three-dimensional MR maximum intensity projection for the assessment of synovitis of the hand and wrist in rheumatoid arthritis: A pilot study. Eur J Radiol 2014; 83: 797-800.
13. Lubrano E, Marchesoni A, Olivieri I, D’Angelo S, Palazzi C, Scarpa R, Ferrara N, Parsons WJ, Brunese L, Helliwell PS, Spadaro A. The radiological assessment of axial involvement in psoriatic arthritis. J Rheumatol 2012; 39: 54-56.
14. Grassi W, Salaffi F, Filippucci E. Ultrasound in rheumatology. Best Pract Res Clin Rheumatol 2005; 19: 467-85.
15. Rezaei H, Torp-Pedersen S, af Klint E, Backheden M, Kisten Y, Gyori N, van Vollenhoven RF. Diagnostic util-
of musculoskeletal ultrasound in patients with suspected arthritis—a probabilistic approach. Arthritis Res Ther 2014; 16: 448.
16. Mandl P, Balint PV, Brault Y, Backhaus M, D’Agostino MA, Grassi W, van der Heijde D, de Miguel E, Wakefield RJ, Logeart I, Dougados M. Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. Arthritis Rheum 2012; 64: 1272-82.
17. Wakefield RJ, Green MJ, Marzo-Ortega H, Conaghan PG, Gibbon WW, McDonagle D, Proudman S, Emery P. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004; 63: 382-5.
18. Karim Z, Wakefield RJ, Quinn M, Conaghan PG, Brown AK, Veale DJ, O’Connor P, Reece R, Emery P. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: a comparison with arthroscopy and clinical examination. Arthritis Rheum 2004; 50: 387-94.
19. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol 1998; 27 Suppl 1: S18-24.
20. Klauser AS, Moriggl B, Duftner C, Smekal V, Pallwein L, Mur E, Schirmer M. Sonography of synovial and erosive inflammatory changes. Radiolgie 2006; 46: 365-75.
21. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP, Swen WA, Wakefield RJ, Manger B, Working Group for Musculoskeletal Ultrasound in the ESCoICSiTT. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001; 60: 641-9.
22. Pinto A, Pinto F, Faggian A, Rubini G, Caracci F, Macarini L, Genovese EA, Brunese L. Sources of error in emergency ultrasonography. Crit Ultrasound J 2013; 5: 1-5.
23. Wakefield RJ, Balint PV, Szkudlarek M, Filippucci E, Backhaus M, D’Agostino MA, Sanchez EN, Iagnocco A, Schmidt WA, Bruyn GA, Kane D, O'Connor P, Manger B, Joshua F, Koski J, Grassi W, Lassere MN, Swen N, Kainberger F, Klausar A, Ostergaard M, Brown AK, Machold KP, Conaghan PG, Group OSI. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32: 2485-7.
24. Iagnocco A, Epis O, Delle Sedie A, Meenagh G, Filippucci E, Riente L, Scire CA, Montecucco C, Bombardieri S, Grassi W, Valesini G. Ultrasound imaging for the rheumatologist. XVII. Role of colour Doppler and power Doppler. Clin Exp Rheumatol 2008; 26: 759-62.
25. Dougados M, Jousse-Joulin S, Mistretta F, d’Agostino MA, Backhaus M, Bentin J, Chales G, Chary-Valckaerena I, Conaghan P, Etchepare F, Gaudio P, Grassi W, van der Heijde D, Sellam J, Naredo E, Szkudlarek M, Wakefield R, Saraux A. Evaluation of several ultrasonography scoring systems for synovitis and comparison to clinical examination: results from a prospective multicentre study of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 828-33.
26. Weidekamm C, Koller M, Weber M, Kainberger F. Diagnostic value of high-resolution B-mode and doppler sonography for imaging of hand and finger joints in rheumatoid arthritis. Arthritis Rheum 2003; 48: 325-33.
Eco-color-power Doppler US and contrast enhanced MRI in joint synovitis

51. Salaffi F, Ciapetti A, Gasparini S, Carotti M, Filippucci E, Grassi W. A clinical prediction rule combining routine assessment and power Doppler ultrasonography for predicting progression to rheumatoid arthritis from early-onset undifferentiated arthritis. Clin Exp Rheumatol 2010; 28: 686-94.

52. Filer A, de Pablo P, Allen G, Nightingale P, Jordan A, Jobanputra P, Bowman S, Buckley CD, Raza K. Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann Rheum Dis 2011; 70: 500-7.

53. Gutierrez M, Filippucci E, Salaffi F, Di Geso L, Grassi W. Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level. Ann Rheum Dis 2011; 70: 1111-4.

54. Ritchlin CT. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17: 406-12.

55. Benjamin M, Morrical B, Brenner E, Emery P, McGonagle D, Redman S. The “enthesis organ” concept: why enthesopathies may not present as focal insertional disorders. Arthritis Rheum 2004; 50: 3306-13.

56. Rettenbacher T, Ennemoser S, Weirich H, Ulmer H, Hartig F, Klotz W, Herold M. Diagnostic imaging of gout: comparison of high-resolution US versus conventional X-ray. Eur Radiol 2008; 18: 621-30.

57. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007; 46: 1116-21.

58. Dalbeth N, Doyle AJ. Imaging of gout: an overview. Best Pract Res Clin Rheumatol 2012; 26: 823-38.

59. Vlchou M, Koutroumpas A, Alexiou I, Pezoulidis I, Sakkas L. High-resolution ultrasonography and 3.0 T magnetic resonance imaging in erosive and nodal hand osteoarthritis: high frequency of erosions in nodal osteoarthritis. Clin Rheumatol 2013; 32: 755-62.

60. Haugen IK, Boyesen P, Slatkowsky-Christensen B, Sesseng S, Bijsterbosch J, van der Heijde D, Kvien TK. Comparison of features by MRI and radiographs of the interphalangeal finger joints in patients with hand osteoarthritis. Ann Rheum Dis 2012; 71: 345-50.

61. Vrquistgaard E, Rogind H, Torp-Pedersen S, Terslev L, Dannefeld-Samsoe B, Bliddal H. quantitative ultrasound in rheumatoid arthritis: evaluation of inflammation by Doppler technique. Ann Rheum Dis 2001; 60: 690-3.

62. Fukuba E, Yoshizako T, Kitagaki H, Murakawa Y, Kondo M, Uchida N. Power Doppler ultrasonography for assessment of rheumatoid synovitis: comparison with dynamic magnetic resonance imaging. Clin Imaging 2013; 37: 134-7.

63. Kiris A, Olgocmen S, Kocakoc E, Ardicoglu O. Power Doppler assessment of overall disease activity in patients with rheumatoid arthritis. J Clin Ultrasound 2006; 34: 5-11.

64. Naredo E, Bonilla G, Gamero F, Uson J, Carmona L, Laffon A. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005; 64: 375-81.

65. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M. Interobserver agreement in
ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 2003; 48: 955-62.
66. Stone M, Bergin D, Whelan B, Maher M, Murray J, McCarthy C. Power Doppler ultrasonography assessment of rheumatoid hand synovitis. J Rheumatol 2001; 28: 1979-82.
67. Albrecht K, Muller-Ladner U, Strunk J. Quantification of the synovial perfusion in rheumatoid arthritis using Doppler ultrasonography. Clin Exp Rheumatol 2007; 25: 630-8.
68. Koski JM, Saarakkala S, Helle M, Hakulinen U, Heikkinnen JO, Hermunen H, Balint P, Bruyn GA, Filippucci E, Grassi W, Iagnocco A, Luosujarvi R, Manger B, de Miguel M, Naredo E, Scheel AK, Schmidt WA, Soini I, Szudlarek M, Terslev L, Uson J, Vuoristo S, Ziswiler HR. Assessing the intra- and inter-reader reliability of dynamic ultrasound images in power Doppler ultrasonography. Ann Rheum Dis 2006; 65: 1658-60.
69. Naredo E, Moller I, Moragues C, de Agustin JJ, Scheel AK, Grassi W, de Miguel E, Backhaus M, Balint P, Bruyn GA, D’Agostino MA, Filippucci E, Iagnocco A, Kane D, Koski JM, Mayordomo L, Schmidt WA, Swen WA, Szudlarek M, Terslev L, Torp-Pedersen S, Uson J, Wakefield RJ, Werner C, Ultrasound EWGfM. Ultrasound interobserver reliability in musculoskeletal ultrasonography: results from a “Teach the Teachers” rheumatologist course. Ann Rheum Dis 2006; 65: 14-9.
70. Wakefield RJ, D’Agostino MA, Iagnocco A, Filippucci E, Backhaus M, Scheel AK, Joshu F, Naredo E, Schmidt WA, Grassi W, Moller I, Pineda C, Klauser A, Szudlarek M, Terslev L, Balint P, Bruyn GA, Swen WA, Jousse-Joulin S, Kane D, Koski JM, O’Connor P, Mitulovinov S, Conaghan PG, Group OU. The OMERACT Ultrasound Group: status of current activities and research directions. J Rheumatol 2007; 34: 848-51.
71. Scheel AK, Schmidt WA, Hermann KG, Bruyn GA, D’Agostino MA, Grassi W, Iagnocco A, Koski JM, Machold KP, Naredo E, Sattler H, Swen WA, Szudlarek M, Wakefield RJ, Ziswiler HR, Pasewaldt D, Werner C, Backhaus M. Interobserver reliability of rheumatologists performing musculoskeletal ultrasonography: results from a EULAR “Train the trainers” course. Ann Rheum Dis 2006; 65: 1043-9.
72. Fukae J, Tanimura K, Atsuma T, Koike T. Sonographic synovial vascularity of synovitis in rheumatoid arthritis. Rheumatology (Oxford) 2014; 53: 586-91.
73. Barile A, Bruno F, Mariani S, Arrigoni F, Brunese L, Zappia M, Splendiani A, Di Cesare E, Masciocchi C. Follow-up of surgical and minimally invasive treatment of Achilles tendon pathology: a brief diagnostic imaging review. Musculoskeletal Surg 2017; 101: 51-61.
74. Cupek R, Ziebinski A. Automated assessment of joint synovitis activity from medical ultrasound and power doppler examinations using image processing and machine learning methods. Rheumatol Int 2016; 36: 239-242.
75. Schmidt WA, Schonau V, Reiche BE, Oberdorfer PD, Ohrndorf S, Backhaus M. Grading of ultrasound Doppler signals in synovitis: does it need an update? Rheumatology (Oxford) 2015; 54: 1897-903.
76. Barile A, Arrigoni F, Bruno F, Guglielmi G, Zappia M, Reginelli A, Ruscitti P, Cipriani P, Giacomelli R, Brunese L, Masciocchi C. Computed Tomography and MR Imaging in Rheumatoid Arthritis. Radiol Clin North Am 2017; 77. Naredo E, Rodriguez M, Campos C, Rodriguez-Heredia JM, Medina JA, Giner E, Martinez O, Toyos FJ, Ruiz T, Ros I, Pujol M, Miquel X, Garcia L, Aznar JJ, Chamizo E, Paez M, Morales P, Rueda A, Tuneu R, Corominas H, de Agustin J, Moragues C, Miguez D, Willisch A, Gonzalez-Cruz I, Aragon A, Iglesias G, Armas C, Pablo Valdazo J, Vargas C, Calvo-Alen J, Juan-Mas A, Salvador G, Pugidollers A, Galindez E, Garrido N, Salaberri J, Raya E, Salles M, Diaz C, Cuadra JL, Garrido J. Ultrasound Group of The Spanish Society of R. Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59: 515-22.
78. Hama M, Uehara T, Takase K, Ihata A, Ueda A, Takeno M, Shizukuishi K, Tatische U, Ishigatsubo Y. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data. Rheumatol Int 2012; 32: 1327-33.
79. Dougados M, Devauchelle-Pensec V, Ferlet JF, Jousse-Joulin S, D’Agostino MA, Backhaus M, Bentin J, Chales G, Chary-Valkenaere I, Conaghan P, Wakefield RJ, Etchepare F, Gaudin P, Grassi W, Heijde D, Mariette X, Naredo E, Szudlarek M. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2013; 72: 665-71.
80. Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford) 2014; 53: 2110-8.
81. Haavardsholm EA, Lie E, Lillegren S. Should modern imaging be part of remission criteria in rheumatoid arthritis? Best Pract Res Clin Rheumatol 2012; 26: 767-85.
82. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O’Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
83. Vreju FA, Filippucci E, Gutierrez M, Di Geso L, Ciapetti A, Ciurea ME, Salaffi F, Grassi W. Subclinical ultrasound synovitis in a particular joint is associated with ultrasound evidence of bone erosions in that same joint in rheumatoid patients in clinical remission. Clin Exp Rheumatol 2016; 34: 673-8.
84. Sudol-Szpinska I, Jans L, Teh J. Rheumatoid arthritis: what do MRI and ultrasound show. J Ultrasound 2017; 17: 5-16.
85. Naredo E, Moller I, Cruz A, Carmona L, Garrido J. Power
Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 2248-56.

86. Albrecht K, Grob K, Lange U, Muller-Ladner U, Strunk J. Reliability of different Doppler ultrasound quantification methods and devices in the assessment of therapeutic response in arthritis. Rheumatology (Oxford) 2008; 47: 1521-6.

87. Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis 2006; 65: 1433-7.

88. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Wakefield R, Karim Z, Quinn M, Hensor E, Conaghan PG, Emery P. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis 2011; 70: 792-8.

89. Klauser A, Demharter J, De Marchi A, Sureda D, Barile A, Filippucci E, Iagnocco A, Salaffi F, Cerioni A, Valesini G, Grassi W. Power Doppler sonography monitoring of synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids. J Rheumatol 2010; 37: 2493-501.

90. Filippucci E, Farina A, Carotti M, Salaffi F, Grassi W. Grey scale and power Doppler sonographic changes induced by intra-articular steroid injection treatment. Ann Rheum Dis 2004; 63: 740-3.

91. Klauser A, Demharter J, De Marchi A, Sureda D, Barile A, Masciocchi C, Faletti C, Schirmer M, Kleffel T, Bohndorf K, group Is. Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group. Eur Radiol 2005; 15: 2404-10.

92. Moutende G, Carotti M, D’Agostino MA. Contrast-enhanced ultrasound in musculoskeletal diseases. J Radiol 2009; 90: 148-55.

93. Klauser AS. Value of contrast-enhanced ultrasound in rheumatic disease. Eur Radiol 2005; 15 Suppl 5: E117-22.

94. Klauser A, Frauscher F, Schirmer M, Kleffel T, Bohndorf K, group Is. Contrast enhanced color Doppler ultrasound in the detection of vascularity of finger joints in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 647-53.

95. Kleffel T, Demharter J, Wohlgemuth W, Schalm J, Bohndorf K, Kirchhof K. Comparison of contrast-enhanced low mechanical index (Low MI) sonography and unenhanced B-mode sonography for the differentiation between synovitis and joint effusion in patients with rheumatoid arthritis. Rofo 2005; 177: 835-41.

96. Schmidt WA, Volker L, Zacher J, Schlafke M, Ruhneke M, Gromnicca-Ihle E. Colour Doppler ultrasonography to detect pannus in knee joint synovitis. Clin Exp Rheumatol 2000; 18: 439-44.
107. Lee CH, Srikhum W, Burghardt AJ, Virayavanich W, Im-
boden JB, Link TM, Li X. Correlation of structural abnor-
malities of the wrist and metacarpophalangeal joints evalu-
ated by high-resolution peripheral quantitative computed
tomography, 3 Tesla magnetic resonance imaging and con-
ventional radiographs in rheumatoid arthritis. Int J Rheu-
matol Dis 2015; 18: 628-39.

108. Ghanem N, Uhl M, Pache G, Bley T, Walker UA, Langer
M. MRI in psoriatic arthritis with hand and foot involve-
ment. Rheumatol Int 2007; 27: 387-93.

109. Narvaez J, Narvaez JA, de Albert M, Gomez-Vaquero C,
Nolla JM. Can magnetic resonance imaging of the hand
and wrist differentiate between rheumatoid arthritis and
psoriatic arthritis in the early stages of the disease? Semin
Arthritis Rheum 2012; 42: 234-45.

110. Lubrano E, Parsons WJ, Marchesoni A, Olivieri I,
D’Angelo S, Cauili A, Caso F, Costa L, Scarpa R, Brunese
L. The definition and measurement of axial psoriatic
arthritis. J Rheumatol 2015; 93: 40-42.

111. Krabben A, Stomp W, van Nies JA, Huizinga TW, van
der Heijde D, Bloem JL, Reijnierse M, van der Helm-van
Mil AH. MRI-detected subclinical joint inflammation is
associated with radiographic progression. Ann Rheum Dis
2014; 73: 2034-7.

112. Dill T. Contraindications to magnetic resonance imaging:
non-invasive imaging. Heart 2008; 94: 943-8.

113. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries
JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Lu-
thra HS, et al. The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid
arthritis. Arthritis Rheum 1988; 31: 315-24.

114. Boutryn N, Morel M, Flipo RM, Demondion X, Cotten A.
Early rheumatoid arthritis: a review of MRI and sonogra-
ic findings. AJR Am J Roentgenol 2007; 189: 1502-9.

115. Eijbjerg B, Narvestad E, Rostrup E, Szkudlarek M, Jacob-
sen S, Thomsen HS, Ostergaard M. Magnetic resonance
imaging of wrist and finger joints differentiate between rheu-
atoid arthritis and osteoarthritis: comparison with the macroscopic and microscopic appearance of the
synovium. Arthritis Rheum 1997; 40: 1856-67.

116. Ostergaard M, Stoltenberg M, Lovgren-Nielsen P, Volck
B, Jensen CH, Lorenzen I. Quantification of syn-
ovitis by MRI: correlation between dynamic and static
gadolinium-enhanced magnetic resonance imaging and
microscopic and macroscopic signs of synovial inflamma-
tion. Magn Reson Imaging 1998; 16: 743-54.

117. Ostergaard M, Peterfy C, Conaghan PG, McQueen F, Bird
P, Eijbjerg B, Shnier R, O’Connor P, Klarlund M, Emery P,
Genant H, Lassere M, Edmonds J. OMERACT Rheuma-
toid Arthritis Magnetic Resonance Imaging Studies. Core
set of MRI acquisitions, joint pathology definitions, and
the OMERACT RA-MRI scoring system. J Rheumatol
2003; 30: 1385-6.

118. Mariani S, La Marra A, Arrigoni F, Necozione S, Splend-
diani A, Di Cesare E, Barile A, Menciocchi C. Dynamic
measurement of patello-femoral joint alignment using
weight-bearing magnetic resonance imaging (WB-MRI).
Eur J Radiol 2015; 84: 2571-2578.

119. Narvaez JA, Narvaez J, Roca Y, Aguiler C. MR imaging
assessment of clinical problems in rheumatoid arthritis.
Eur Radiol 2002; 12: 1819-28.

120. Sugimoto H, Takeda A, Hyodo K. Early-stage rheuma-
toid arthritis: prospective study of the effectiveness of MR
imaging for diagnosis. Radiology 2000; 216: 569-75.

121. Tamai M, Kawakami A, Uetani M, Takao S, Rashid H,
Tanaka F, Fujikawa K, Arakami T, Nakamura H, Iwanaga
N, Izumi Y, Arima K, Aratake K, Kamachi M, Huang M,
Oriuchi T, Ida H, Aoyagi K, Eguchi K. Early prediction of rheumatoid arthritis by omitting intravenous contrast injection
-- Does it change the assessment of inflammatory and de-
structive joint changes by the OMERACT RAMRIS? J Rheumatol 2009; 36: 1806-10.

132. Ostergaard M, Klarlund M. Importance of timing of post-contrast MRI in rheumatoid arthritis: what happens during the first 60 minutes after IV gadolinium-DTPA? Ann Rheum Dis 2001; 60: 1050-4.

133. Caranci F, Leone G, Ugga L, Cesarano E, Capasso R, Schipani S, Bianco A, Fonio P, Brignati F, Brunese L. Imaging of post-surgical treatment and of related complications in spinal trauma. Musculoskeletal Surg 2017; 101: 63-73.

134. Splendiani A, D’Orazio F, Patriarca L, Arrigoni F, Caranci F, Fonio P, Brunese L, Barile A, Di Cesare E, Masciocchi C. Imaging of post-operative spine in intervertebral disc pathology. Musculoskeletal Surg 2017; 101: 75-84.

135. Weber U, Hodler J, Kubik RA, Rüfihach K, Lambert RG, Kissling RO, Pfirrmann CW, Maksymowycz WP. Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent-onset inflammatory back pain. Arthritis Rheum 2009; 61: 900-8.

136. Klarlund M, Ostergaard M, Rostrup E, Skjodt H, Lorenzen I. Dynamic magnetic resonance imaging of the metacarpophalangeal joints in rheumatoid arthritis, early unclassified polyarthritis, and healthy controls. Scand J Rheumatol 2000; 29: 108-15.

137. Eibjerg B, McQueen F, Lassere M, Haavardsholm E, Conaghan P, O’Connor P, Bird P, Peterfy C, Edmonds J, Szkudlarek M, Genant H, Emery P, Ostergaard M. The EULAR-OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint. Ann Rheum Dis 2005; 64 Suppl 1: i23-47.

138. Yamato M, Tamai K, Yamaguchi T, Ohno W. MRI of the knee in rheumatoid arthritis: Gd-DTPA perfusion dynamics. J Comput Assist Tomogr 1993; 17: 781-5.

139. Huang J, Stewart N, Crabbe J, Robinson E, McLean L, Yeoman S, Tan PL, McQueen FM. A 1-year follow-up study of dynamic magnetic resonance imaging in early rheumatoid arthritis reveals synovitis to be increased in shared epitope-positive patients and predictive of erosions at 1 year. Rheumatology (Oxford) 2000; 39: 407-16.

140. van de Sande MG, van der Leij C, Lavini C, Wijbrandts CA, Maas M, Tak PP. Characteristics of synovial inflammation in early arthritis analysed by pixel-by-pixel time-intensity curve shape analysis. Rheumatology (Oxford) 2012; 51: 1240-5.

141. Vordenbaumen S, Schleich C, Logters T, Sewerin P, Bleck E, Pauly T, Muller-Lutz A, Antoch G, Schneider M, Miese F, Ostendorf B. Dynamic contrast-enhanced magnetic resonance imaging of metacarpophalangeal joints reflects histological signs of synovitis in rheumatoid arthritis. Arthritis Res Ther 2014; 16: 452.

142. Konig H, Sieper J, Wolf KJ. Rheumatoid arthritis: evaluation of hypervascular and fibrous pannus with dynamic MR imaging enhanced with Gd-DTPA. Radiology 1990; 176: 473-7.

143. Gaffney K, Cookson J, Blake D, Coumbe A, Blades S. Quantification of rheumatoid synovitis by magnetic resonance imaging. Arthritis Rheum 1995; 38: 1610-7.

144. Tamai K, Yamato M, Yamaguchi T, Ohno W. Dynamic magnetic resonance imaging for the evaluation of synovitis in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 1151-7.

145. Boutry N, Hachulla E, Flipo RM, Cortet B, Cotten A. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjogren syndrome. Radiology 2005; 236: 593-600.

146. Cimmino MA, Parodi M, Innocenti S, Succio G, Banderali S, Silvestri E, Garlaschi G. Dynamic magnetic resonance of the wrist in psoriatic arthritis reveals imaging patterns similar to those of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R725-31.

147. Savnik A, Malmskov H, Thomsen HS, Graff LB, Nielsen H, Danneksloid-Samsoe B, Boesen J, Bliddal H. MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions. Eur Radiol 2002; 12: 1203-10.

148. Jevtic V, Watt I, Rozman B, Kos-Golja M, Demsar F, Jarh O. Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthristis demonstrated by contrast-enhanced (Gd-DT PA) magnetic resonance imaging. Skeletal Radiol 1995; 24: 351-5.

149. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-6.

150. McQueen F, Lassere M, Ostergaard M. Magnetic resonance imaging in psoriatic arthritis: a review of the literature. Arthritis Res Ther 2006; 8: 207.

151. Cimmino MA, Zampogna G, Parodi M, Andracco R, Barbieri F, Paparo F, Ferrero G, Garlaschi G. MRI synovitis and bone lesions are common in acute gouty arthritis of the wrist even during the first attack. Ann Rheum Dis 2011; 70: 2238-9.

152. Loeuille D, Chary-Valkenaere I, Champigneulle J, Rat AC, Toussaint F, Pinzano-Watrin A, Goebel JC, Mainard D, Blum A, Pourel J, Netter P, Gillet P. Macroscopic and microscopic features of synovial membrane inflammation in the osteoarthritic knee: correlating magnetic resonance imaging findings with disease severity. Arthritis Rheum 2005; 52: 3492-501.

153. Kirkhus E, Bjornerud A, Thoen J, Johnston V, Dale K, Jarh O. Distinctive radiological features of small hand joints in rheumatoid arthritis and seronegative spondyloarthristis demonstrated by contrast-enhanced (Gd-DTPA) magnetic resonance imaging. Skeletal Radiol 1995; 24: 351-5.

154. Savnik A, Malmskov H, Thomsen HS, Graff LB, Nielsen H, Danneksloid-Samsoe B, Boesen J, Bliddal H. MRI of the wrist and finger joints in inflammatory joint diseases at 1-year interval: MRI features to predict bone erosions. Eur Radiol 2002; 12: 1203-10.

155. Sugimoto H, Takeda A, Masuyama J, Furuse M. Early-
stage rheumatoid arthritis: diagnostic accuracy of MR imaging. Radiology 1996; 198: 185-92.

156. Østergaard M, Gideon P, Henriksen O, Lorenzen L. Synovial volume—a marker of disease severity in rheumatoid arthritis? Quantification by MRI. Scand J Rheumatol 1994; 23: 197-202.

157. Workie DW, Dardzinski BJ. Quantifying dynamic contrast-enhanced MRI of the knee in children with juvenile rheumatoid arthritis using an arterial input function (AIF) extracted from popliteal artery enhancement, and the effect of the choice of the AIF on the kinetic parameters. Magn Reson Med 2005; 54: 560-8.

158. Hodgson RJ, O'Connor P, Moots R. MRI of rheumatoid arthritis image quantitation for the assessment of disease activity, progression and response to therapy. Rheumatology (Oxford) 2008; 47: 13-21.

159. Andersen M, Boesen M, Ellegaard K, Christensen R, Soderstrom K, Soe N, Spee P, Morch UG, Torp-Pedersen S, Bartels EM, Danneskiold-Samsoe B, Vendel N, Karlsson L, Bliddal H. Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks: a cross-sectional study. Arthritis Res Ther 2014; 16: R107.

160. Østergaard M, Stoltenberg M, Henriksen O, Lorenzen L. Quantitative assessment of synovial inflammation by dynamic gadolinium-enhanced magnetic resonance imaging. A study of the effect of intra-articular methylprednisolone on the rate of early synovial enhancement. Br J Rheumatol 1996; 35: 50-9.

161. Carubbi F, Zugaro L, Cipriani P, Conchiglia A, Gregori L, Danniballe C, Letizia Pistoia M, Liakouli V, Ruscitti P, Ciccio F, Triolo G, Masciocchi C, Giacomelli R. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol. 2015; 29: 252-266.

162. Barile A, La Marra A, Arrigoni F, Mariani S, Zugaro L, Splendiani A, Di Cesare E, Reginelli A, Zappa M, Brunese L, Duka E, Carrafiello G, Masciocchi C. Anaesthetic, steroids and platelet-rich plasma (PRP) in ultrasound-guided musculoskeletal procedures. Br J Radiol. 2016; 89:

163. Hodgson R, Grainger A, O’Connor P, Barnes T, Connolly S, Moots R. Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid arthritis. Ann Rheum Dis 2008; 67: 270-2.

164. Palosaari K, Vuotila J, Takalo R, Jartti A, Niemela R, Haapea M, Soini I, Tervonen O, Hakala M. Contrast-enhanced dynamic and static MRI correlates with quantitative 99Tc-labelled nanocolloid scintigraphy. Study of early rheumatoid arthritis patients. Rheumatology (Oxford) 2004; 43: 1364-73.

165. Cyteval C, Miquel A, Hoa D, Daures JP, Mariette X, Combe B. Rheumatoid arthritis of the hand: monitoring with a simplified MR imaging scoring method—preliminary assessment. Radiology 2010; 256: 863-9.

166. McQueen F, Lassere M, Bird P, Haavardsholm EA, Peterfy C, Conaghan PG, Ejbjerg B, Genant H, O’Connor P, Emery P, Østergaard M. Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. J Rheumatol 2007; 34: 859-61.

167. Østergaard M, Eder L, Christiansen SN, Kaeley GS. Imaging in the diagnosis and management of peripheral psoriatic arthritis: The clinical utility of magnetic resonance imaging and ultrasonography. Best Pract Res Clin Rheumatol 2016; 30: 624-637.

168. Glinatsi D, Bird P, Gandjbakhch F, Mease PJ, Boyesen P, Peterfy CG, Conaghan PG, Østergaard M. Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial. J Rheumatol 2015; 42: 2473-9.

169. Kosta PE, Voulgari PV, Zikou AK, Drosos AA, Argyropoulou M. The usefulness of magnetic resonance imaging of the hand and wrist in very early rheumatoid arthritis. Arthritis Res Ther 2011; 13: R84.

170. Stomp W, Krabben A, van der Heijde D, Huizinga TW, Bloem JL, van der Helm-van Mil AH, Reijnierse M. Are rheumatoid arthritis patients discernible from other early arthritis patients using 1.5T extremity magnetic resonance imaging? a large cross-sectional study. J Rheumatol 2014; 41: 1630-7.

171. Ostendorf B, Scherer A, Modder U, Schneider M. Diagnostic value of magnetic resonance imaging of the metacarpophalangeal joints of the hands remain normal. Arthritis Rheum 2004; 50: 2094-102.

172. Mundwiler ML, Marianian P, Brown DH, Silverman JM, Wallace D, Khanna D, Louie J, Furst DE, Weisman MH. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthritis Res Ther 2009; 11: R94.

173. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.

174. Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 675-88.

175. Peterfy CG. Magnetic resonance imaging of rheumatoid arthritis: the evolution of clinical applications through clinical trials. Semin Arthritis Rheum 2001; 30: 375-96.

176. Freeston JE, Bird P, Conaghan PG. The role of MRI in rheumatoid arthritis: research and clinical issues. Curr Opin Rheumatol 2009; 21: 95-101.
177. Duer-Jensen A, Horslev-Petersen K, Høtland ML, Bak L, Ejbjerg BJ, Hansen MS, Johansen JS, Lindegaard HM, Vinterberg H, Møller JM, Ostergaard M. Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum 2011; 63: 2192-202.

178. Eguchi K. Early prediction of joint destruction in rheumatoid arthritis. Clin Calcium 2007; 17: 517-25.

179. Guermazi A, Taouli B, Lynch JA, Peterfy CG. Imaging of bone erosion in rheumatoid arthritis. Semin Musculoskelet Radiol 2004; 8: 269-85.

180. McQueen FM, Dalbeth N. Predicting joint damage in rheumatoid arthritis using MRI scanning. Arthritis Res Ther 2009; 11: 124.

181. Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002; 46: 507-13.

182. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, McLean L, Stewart N. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1814-27.

183. Haavardsholm EA, Boysen P, Ostergaard M, Schild-vold A, Kviën TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008; 67: 794-800.

184. Hetland ML, Ejbjerg BJ, Horslev-Petersen K, Jacobsen S, Vestergaard A, Junik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjodt H, Pedersen JK, Maigaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallo J, Torfing T, Nørvestad E, Thomsen HS, Ostergaard M, group Cs. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009; 68: 384-90.

185. Bollow M, Fischer T, Reischauer H, Backhaus M, Sieper J, Hamm B, Braun J. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active spondylitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59: 135-40.

186. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58: 156-63.

187. Ostergaard M, Dohn UM, Ejbjerg BJ, McQueen FM. Ultrasonography and magnetic resonance imaging in early rheumatoid arthritis: recent advances. Curr Rheumatol Rep 2006; 8: 378-85.

188. Olech E, Freeston JE, Conaghan PG, Hensor EM, Emery P, Yocum D. Using extremity magnetic resonance imaging to assess and monitor early rheumatoid arthritis: the optimal joint combination to be scanned in clinical practice. J Rheumatol 2008; 35: 580-3.

189. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O’Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-67.

190. Backhaus M, Burmester GR, Sandrock D, Loreck D, Hess D, Scholz A, Blind S, Hamb M, Bollow M. Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis 2002; 61: 895-904.

191. Tonolli-Serabian I, Poet JL, Dufour M, Carasset S, Mattee JP, Roux H. Magnetic resonance imaging of the wrist in rheumatoid arthritis: comparison with other inflammatory joint diseases and control subjects. Clin Rheumatol 1996; 15: 137-42.

192. Conaghan PG, O’Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, Quinn M, Karim Z, Green MJ, Proudman S, Isaacs J, Emery P. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003; 48: 64-71.

193. Ostergaard M, Hansen M, Stoltenberg M, Gideon P, Klarlund M, Jensen KE, Lorenzen I. Magnetic resonance imaging—determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 918-29.

194. Ostergaard M, Stoltenberg M, Gideon P, Sørensen K, Henriksen O, Lorenzen I. Changes in synovial membrane and joint effusion volumes after intraarticular methylprednisolone. Quantitative assessment of inflammatory and destructive changes in arthritis by MRI. J Rheumatol 1996; 23: 1151-61.

195. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schools M, Aletaha D, Buch M, Gosses L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cudolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.

196. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skjodt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, Podenphant J, Hansen G, Lindegaard H, de Carvalho A, Ostergaard M, Horslev-Petersen K, Group CS. Combination
treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54: 1401-9.

197. Nell VP, Machold KP, Eberl G, Stamma TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906-14.

198. Lillegren S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kviens TK, Haavardsholm EA, Weinblatt ME, Solomon DH. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012; 71: 681-6.

199. Tavares R, Pope JE, Tremblay JL, Thorne C, Bykerk VP, Lazowskis J, Blocka KL, Bell MJ, Lacalle D, Hitchon CA, Fitzgerald AA, Fidler WK, Bookman AA, Henderson JM, Mosher DP, Sholter DE, Khraishi M, Harauyi B, Chen H, Li X, Laupacis A, Boire G, Tomlinson G, Bombardier C. Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. J Rheumatol 2011; 38: 2342-5.

200. Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, Friedlund B, Combination of M, Etanercept in Early Rheumatoid Arthritis Trial G. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010; 62: 674-82.

201. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995; 98: 156-68.

202. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Emery P, Breedveld D, Ferraccioli G, Fitzgerald AA, Fidler WK, Bookman AA, Henderson JM, Mosher DP, Sholter DE, Khraishi M, Harauyi B, Chen H, Li X, Laupacis A, Boire G, Tomlinson G, Bombardier C. Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. J Rheumatol 2011; 38: 2342-5.

203. Mottonen T, Hanninen P, Korpela M, Nissila M, Kauitainen H, Ilonen J, Laasonen L, Kaipainen-Seppanen O, Franzen P, Helve T, Koski J, Gripenberg-Gahnberg M, Myllykangas-Luosujarvi R, Leirisalo-Repo M, therapy FI-RTGFRAC. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.

204. Egsmose C, Lund B, Borg G, Petersson H, Berg E, Brodin U, Trang L. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.

205. Zikou AK, Argyroupoulos M, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, Drosos AA. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J Rheumatol 2006; 33: 219-23.

206. Haavardsholm EA, Ostergaard M, Hammer HB, Boyesen P, Boosen A, van der Heijde D, Kviens TK. Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann Rheum Dis 2009; 68: 1572-9.

207. Ostergaard M, Emery P, Conaghan PG, Fleischmann R, Hsa EC, Xu W, Rahman MU. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis Rheum 2011; 63: 3712-22.

208. Eijbjerg BJ, Vestergaard A, Jacobsen S, Thomsen HS, Ostergaard M. The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthritis Rheum 2005; 52: 2300-6.

209. Schaefter JF, Schlemmer HP. Total-body MR-imaging in oncology. Eur Radiol 2006; 16: 2000-15.

210. Naed K, Ruehm SG, Michaeley HJ, Saleh R, Lee M, Laub G, Finn JP. Multistation whole-body high-spatial-resolution MR angiography using a 32-channel MR system. AJR Am J Roentgenol 2007; 188: 529-39.

211. Weber U, Pfirrmann CW, Kissling RO, Hodler J, Zenetti M. Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord 2007; 8: 20.

212. Aquino MR, Tse SM, Gupta S, Rachlis AC, Stimec J. Whole-body MRI of juvenile spondyloarthritis: protocols and pictorial review of characteristic patterns. Pediatr Radiol 2015; 45: 754-62.

213. Strunk J, Lange U. Three-dimensional power Doppler sonographic visualization of synovial angiogenesis in rheumatoid arthritis. J Rheumatol 2004; 31: 1004-6.

214. Naredo E, Acebes C, Brito E, de Agustin JJ, de Miguel E, Mayordomo L, Moller I, Moragues C, Rejon E, Rodriguez A, Uson J, Garrido J, Martinez-Hernandez D, Ultrasound School of the Spanish Society of R. Three-dimensional power Doppler sonography of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. J Rheumatol 2006; 33: 219-23.
matologist. XX. Sonographic assessment of hand and wrist joint involvement in rheumatoid arthritis: comparison between two- and three-dimensional ultrasonography. Clin Exp Rheumatol 2009; 27: 197-200.

216. Filippucci E, Meenagh G, Epis O, Iagnocco A, Riente L, Delle Sedie A, Montecucco C, Valesini G, Bombardieri S, Grassi W. Ultrasound imaging for the rheumatologist. XIII. New trends. Three-dimensional ultrasonography. Clin Exp Rheumatol 2008; 26: 1-4.

217. Offidani A, Cellini A, Valeri G, Giovagnoni A. Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol 1998; 78: 463-5.

218. Arrigoni F, Gregori LM, Zugaro L, Barile A, Masciocchi C. MRgFUS in the treatment of MSK lesions: A review based on the experience of the university of L’aquila, Italy. Transl Cancer Res 2014; 3: 442-448.

219. Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A. Gadolinium retention in the body: what we know and what we can do. Radiol. Med. 2017; 122: 589-600.